FDA accepts new drug application for UGN-103 in recurrent LG-IR-NMIBC

관련 기사

1. 13:12Samsung Bioepis' first ADC candidate wins FDA Fast TrackThe Korea Herald
2. 11:38Samsung Bioepis wins FDA Fast Track for 1st anticancer drug candidateThe Korea Times
3. 10:05Samsung Bioepis' First Novel Drug Candidate SBE303 Wins FDA Fast Track DesignationBigGo Finance
4. 10:00Samsung Bioepis Receives FDA Fast Track Designation for SBE303Businesskorea
5. 09:22삼성바이오에피스, '1호 신약' 미국 FDA 패스트트랙 지정데일리팜
6. 08:16삼성바이오에피스 "1호 신약후보 미국 FDA 패스트트랙 지정"연합뉴스
7. 08:10삼성바이오에피스, 'SBE303' 미국 FDA 패스트 트랙 의약품 지정히트뉴스
8. 07:07Is my GLP-1 safe? What to know about FDA's crackdown on copycat drugsUSA Today
9. 05:57GLP-1 injections recalled nationwide over sterility concerns, FDA saysFox Business
10. 10.20메디쎄이, 올해 미국 FDA 510(k) '3연속 인증' 척추 시장 정조준약사공론